Astrazeneca to launch Osimertinib Tablet 40 mg and 80 mg (Tagrisso™) in India after it received nod from Drug Controller General of India. Also stoke pricing of the company is increased by 3 % followed by this announcement.
Osimertinib 40 mg and 80 mg (Tagrisso™) is an oral anti-cancer drug for management of lung cancer. It is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an appropriate test, whose disease has progressed on or after EGFR TKI therapy.
Read more